All News
RWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana
The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13.
Rheumatoid Arthritis Year in Review
Read ArticleRheumatoid Modern Management is Better but More Costly
The mantra of rheumatologists worldwide is to treat rheumatoid arthritis (RA) earlier and more aggressively. While referral of early RA patients has improved, there is little data demonstrating that more aggressive treatment works or is cost effective.
Read ArticleFDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar
On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).
Read ArticleFDA Reviews Celltrion's Remicade Biosimilar Today
The arthritis advisory committee of the Food and Drug Administration (FDA) is scheduled to meet today, February 9th to review the efficacy and safety of Celltrion's biosimilar form of infliximab (Remicade) that is currently marketed in other countries.
Read ArticleRheumatoid Arthritis, TNF inhibitors and the Risk of Skin Cancer
Rheumatoid arthritis (RA) patients are said to have a neutral risk for neoplasia, but this is because they have a lower risk of colon cancer and breast cancer but a higher risk of lung cancer, lymphoma and skin cancers.
Read ArticleBiosimilar of Remicade Works in Ankylosing Spondylitis
CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis (AS), a multinational study found.
Read ArticleNIH-Funded Trials Down, While Industry Trials Increase
(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.
Read ArticleUpdated RA Treat-to-Target International Recommendations
In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).
Read ArticleBiosimilar Reports - January 2016
Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.
Read ArticleRisk of Multiple Sclerosis with TNF Inhibitor Therapy
Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi).
Read ArticleTNF Inhibitors May Increase Cardiac Risks in Elderly
A retrospective study of elderly rheumatoid arthritis (RA) patients on Medicare was conducted by a group of researchers from the University of Alabama.
Read ArticlePALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.
Read ArticleFDA Approves Cosentyx for Ankylosing Spondylitis and Psoriatic Arthritis
Cosentyx (secukinumab) was approved by the FDA on 15 January, 2016 for patients with active ankyosing spondylitis (AS) and psoriatic arthritis (PsA).
Read ArticleCombination or Monotherapy Tocilizumab in Rheumatoid Arthritis
Several rheumatoid arthritis studies have shown that tocilizumab (TCZ) may be as effective as monotherapy when compared to combination therapy (methotrexate plu
Read ArticleGame-Changers 2015: Refining Treatment in Arthritis
Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPa
Read ArticleSecukinumab Shows Efficacy in Two Ankylosing Spondylitis Trials
NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis.
Read ArticleTofacitinib Shows Promise in Alopecia, Eczema and Vitiligo
Tofacitinib has been approved for use in rheumatoid arthritis.
Read Article2015 ACR RA Guidelines Released– Finally! (Best of 2015: #2)
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
Read ArticleThe History of Citrullination (Best of 2015)
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
Read ArticleHow I Choose Biologics (Best of 2015)
Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial.
Read Article